Extended-release niacin (nicotinic acid)/laropiprant.

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Metabolic Disorders

Background:

• Dyslipidemia, characterized by abnormal lipid levels, is a major risk factor for cardiovascular disease.
• Niacin (vitamin B3) is a lipid-modifying agent, but its use is limited by flushing side effects.
• Laropiprant is an anti-flushing agent designed to mitigate niacin-induced flushing.

Purpose of the Study:

• To evaluate the efficacy and tolerability of extended-release (ER) niacin/laropiprant in adults with dyslipidemia.
• To assess the lipid-modifying effects of ER niacin/laropiprant, alone and in combination with statins.
• To determine the impact of laropiprant on niacin-induced flushing.

Main Methods:

• Randomized, double-blind, placebo-controlled, multicentre trials of up to 24 weeks duration.
• Evaluation of ER niacin/laropiprant (2000 mg/40 mg) versus placebo for low-density lipoprotein cholesterol (LDL-C) reduction.
• Assessment of ER niacin/laropiprant combined with simvastatin versus monotherapy for LDL-C improvements and flushing incidence.

Main Results:

• ER niacin/laropiprant significantly reduced LDL-C by 18.4% compared to placebo (p < 0.001).
• Combination therapy with ER niacin/laropiprant and simvastatin showed significant LDL-C improvements versus monotherapy (p < 0.05).
• The incidence and intensity of flushing were significantly reduced with ER niacin/laropiprant compared to ER niacin alone (p < 0.05).

Conclusions:

• ER niacin/laropiprant is an effective treatment for lowering LDL-C in adults with primary hypercholesterolaemia or mixed dyslipidemia.
• The addition of laropiprant significantly reduces flushing associated with niacin therapy.
• ER niacin/laropiprant, alone or with statins, was generally well-tolerated and offers a potential therapeutic option for dyslipidemia management.